Related Experiment Video
Updated: Aug 13, 2026
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
Published on: September 29, 2015
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement:
1Oncologia Medica e Trapianto di Midollo Osseo, Pad. H 5 piano, Policlinico Universitario, Via Consolare Valeria, 98125, Messina, Italia.pitini@ciaoweb.it
Abstract:
Based on its ability to inhibit the tyrosine kinase activity of ABL, as well as the c-kit and the Platelet Derived Growth Factor Receptor tyrosine kinases, the spectrum of diseases that may respond to STI571 is increasing. A recently recognized subgroup of myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS) has a t(5;12)(q33;p13) with the activation of the gene for PDGFBR which encodes a receptor tyrosine kinase. Here, we present the case of a patient, with MPD/MDS, and eosinophilia, carrying a translocation t(5;12)(q33;p13) who achieved a complete remission following treatment with STI571, 400 mg daily. At the time of writing he still remains in complete remission with an excellent performance status. There is clearly a need for further studies of STI 571in MPD/MDS with chromosomal translocations involving PDGFBR to confirm this promising initial result.
Insights
STI571 effectively treated a patient with myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS) and eosinophilia. This condition involved a specific chromosomal translocation, suggesting potential for STI571 in similar MPD/MDS cases.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- STI571 inhibits tyrosine kinases including ABL, c-kit, and Platelet Derived Growth Factor Receptor (PDGFBR).
- Myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS) can involve chromosomal translocations, such as t(5;12)(q33;p13).
- This translocation activates the PDGFBR gene, encoding a receptor tyrosine kinase implicated in certain MPD/MDS subtypes.
Observation:
- A patient diagnosed with MPD/MDS and eosinophilia presented with a t(5;12)(q33;p13) translocation.
- The patient carried the specific chromosomal abnormality involving the PDGFBR gene.
Findings:
- Treatment with STI571 at 400 mg daily resulted in a complete remission for the patient.
- The patient maintained complete remission with an excellent performance status at the time of reporting.
Implications:
- This case highlights the potential efficacy of STI571 in treating MPD/MDS associated with PDGFBR gene rearrangements.
- Further clinical studies are warranted to confirm these promising results in a larger cohort of patients with similar genetic profiles.
- Targeted therapy with STI571 may offer a new treatment avenue for specific MPD/MDS subgroups.
